PD-116 Early versus late chest radiotherapy for limited stage small cell lung cancer: A systematic review and meta-analysis

Pijls, M; Ruysscher, Dirk De; Rutten, Isabelle; Lambin, Philippe; Vansteenkiste, Johan

doi:10.1016/s0169-5002(05)80449-0

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35 Early thoracic irradiation cannot be expected to perform well unless it is coupled with a chemotherapy regimen compatible with concurrent radiotherapy and efficacious enough to improve control of micrometastases outside the thoracic irradiation volume. Parenthetically, the odds ratios adduced in favor of early concurrent thoracic irradiation versus delayed thoracic irradiation (0.80, 0.64, and 0.56) in the meta-analysis by Pijls et al 51 are more favorable than the OR of 0.86 in favor of combined-modality therapy versus chemotherapy alone (0.86). 5 Another factor that influenced the less than robust statistics of the meta-analysis on the timing of thoracic irradiation is that the prognostic factors of the patients in the trials appear different.…”

Section: Sequencing and Timing Of Thoracic Radiotherapymentioning

confidence: 99%

“…Recently, a meta-analysis performed according to the Cochrane Collaboration Guidelines examined randomized controlled clinical trials comparing different timing of chest radiotherapy in patients with LSCLC. 51 Early chest irradiation was defined as beginning within 30 days after the start of chemotherapy. Seven randomized trials were eligible.…”

Section: Sequencing and Timing Of Thoracic Radiotherapymentioning

confidence: 99%

See 1 more Smart Citation

A Review of First-Line Treatment for Small-cell Lung Cancer

Murray¹,

Turrisi²

2006

Journal of Thoracic Oncology

109

View full text Add to dashboard Cite

Although small-cell lung cancer (SCLC) makes up a smaller proportion of all lung cancers than it did 25 years ago, it remains a common cause of cancer mortality that requires more clinical and basic research than is currently underway. Trials of newer chemotherapy variations have failed to produce a regimen that is clearly superior to the two-drug combination of etoposide and cisplatin, which remains the standard of care for both limited and extensive stage SCLC. Paradoxically, advances in this systemic disease have come from radiotherapy innovations for limited SCLC, including addition of thoracic irradiation to systemic chemotherapy, more intense thoracic irradiation, early integration of thoracic irradiation with systemic chemotherapy, and prophylactic cranial irradiation.

show abstract

Section: Sequencing and Timing Of Thoracic Radiotherapymentioning

confidence: 99%

Section: Sequencing and Timing Of Thoracic Radiotherapymentioning

confidence: 99%

A Review of First-Line Treatment for Small-cell Lung Cancer

Murray¹,

Turrisi²

2006

Journal of Thoracic Oncology

109

View full text Add to dashboard Cite

show abstract

“…Recently, a meta-analysis performed according to the Cochrane Collaboration Guidelines examined randomized controlled clinical trials comparing different timing of chest radiotherapy in patients with LSCLC. [5] Early chest irradiation was defined as beginning within 30 days after the start of chemotherapy. Seven randomized trials were eligible.…”

Section: Combined Modality Therapy For Limited Stage Sclcmentioning

confidence: 99%

MTP4-01: Small cell lung cancer

Murray

2007

Journal of Thoracic Oncology

View full text Add to dashboard Cite

technical aspects of incorporating robotic assistance and the perioperative outcomes. MethodsPatients with adequate cardiopulmonary reserve to tolerate lobectomy for clinical stage I NSCLC or other pathologic tumors that were peripheral and confined to the lung were considered eligible for VATS lobectomy. At our institution the procedure is performed using two 1 -1.5 cm access incisions and a ≤ 4 cm non-rib-spreading utility incision with intrathoracic visualization achieved via thoracoscope exclusively. Initial thoracic exploration is conducted with conventional thoracoscopy in order to verify resectability and to establish the three standard VATS lobectomy access incisions. Once the incisions have been made, the da Vinci ® robot is brought into position, the surgical instruments are introduced under direct thoracoscopic vision, and the operating surgeon moves to the surgeonís console. Robotic assistance is defined as use of the da Vinci ® Surgical System during a VATS lobectomy for individual dissection, isolation, and ligation of the pulmonary hilar structures, as well as mediastinal lymph node dissection. Informed consent for robotic assistance during VATS lobectomy was obtained. Data on patient characteristics, operative details and postoperative recovery were collected in a prospective database approved by the institutional review board and analyzed retrospectively. All complications were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (CT-CAE 3.0)(http://ctep.cancer.gov/reporting/ctc.html). ResultsBetween November 2002 and May 2006 there were 63 consecutive patients who underwent attempted robotic-assisted VATS lobectomy employing the da Vinci ® Surgical System. The patient characteristics are listed in the Table . Most of the lesions were located in the upper lobes (44/63, 70%) with right upper lobe tumors being the most common (28). The vast majority of our patients had NSCLC (60/63, 95%), two patients had typical carcinoid tumors, and one had a primary pulmonary lymphoma. Those with NSCLC all were clinical stage IA preoperatively. Eleven patients (17%) had no tissue diagnosis and underwent initial VATS and wedge resection in the same setting. VATS lobectomy using robotic assistance was completed in 58 (92%) patients. Conversion to thoracotomy was required in 5 patients (8%). Three patients were converted for minor bleeding, two from cautery injuries to a segmental pulmonary artery in the course of dissection and one during isolation of the superior pulmonary vein. None of these patients required blood transfusion intraoperatively or postoperatively. One patient required conversion secondary to loss of single lung isolation and one underwent thoracotomy for excessive adhesions and inflammatory nodal disease. The Table shows the perioperative results. Median total operative time was 284 minutes (range 185 -460). Median intrathoracic operative time was 210 minutes (range 143 -350). Of note, the median total and intrathoracic operative time for th...

show abstract

Radiotherapy Guidelines in Small Cell Lung Cancer

2007

Image-Guided Radiotherapy of Lung Cancer

View full text Add to dashboard Cite

PD-116 Early versus late chest radiotherapy for limited stage small cell lung cancer: A systematic review and meta-analysis

Cited by 4 publications

References 0 publications

A Review of First-Line Treatment for Small-cell Lung Cancer

A Review of First-Line Treatment for Small-cell Lung Cancer

MTP4-01: Small cell lung cancer

Radiotherapy Guidelines in Small Cell Lung Cancer

Contact Info

Product

Resources

About